FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2601242481> ?p ?o ?g. }

• W2601242481 endingPage "519" @default.
• W2601242481 startingPage "519" @default.
• W2601242481 abstract "519 Background: Approximately 4% of metastatic colorectal cancers (mCRCs) are associated with high microsatellite instability (MSI-H), indicating a deficient DNA mismatch repair (dMMR) system. dMMR/MSI-H CRC exhibits an increased tumor neoantigen load and immune cell infiltration and is hypothesized to be targetable by immune checkpoint inhibitors. CheckMate 142 (NCT02060188) evaluates the efficacy and safety of nivolumab (nivo) in patients (pts) with dMMR/MSI-H mCRC. Methods: Pts with dMMR/MSI-H mCRC who progressed on/were intolerant to ≥1 prior line of therapy received nivo 3 mg/kg (nivo 3) every 2 weeks (Q2W). The primary endpoint was objective response rate (ORR) per investigator (INV). The secondary endpoint was ORR per independent radiology review committee (IRRC); exploratory endpoints included safety, PFS, OS, and efficacy in biomarker-defined populations. Results: Among pts treated with nivo 3 Q2W (N = 74), 84% had received ≥2 prior lines of therapy. ORRs were 31% (INV) and 27% (IRRC); disease control rates were 69% (INV) and 62% (IRRC). The median time to response was ≈2.7 mo (INV/IRRC). PFS rates at 12 mo were 48.4% (INV) and 45.6% (IRRC). The duration of response and OS medians were not yet reached; OS rates were 83.4% (6 mo) and 73.8% (12 mo). Responses were observed in pts regardless of tumor programmed death-1 ligand 1 (PD-L1) expression level or BRAF or KRAS mutation status and were observed in pts with or without a history of Lynch syndrome (Table). Grade 3–4 treatment-related adverse events (TRAEs) occurred in 20% of pts. TRAEs leading to discontinuation included acute kidney injury, increased ALT, colitis, and stomatitis (1 each). No treatment-related deaths occurred in this arm. Conclusions: Nivo showed durable responses and disease control in heavily pretreated pts with dMMR/MSI-H mCRC. Treatment was well tolerated, with no new safety signals. Clinical trial information: NCT02060188. [Table: see text]" @default.
• W2601242481 created "2017-04-07" @default.
• W2601242481 creator A5003827387 @default.
• W2601242481 creator A5006249276 @default.
• W2601242481 creator A5009193095 @default.
• W2601242481 creator A5022734154 @default.
• W2601242481 creator A5025097010 @default.
• W2601242481 creator A5030715123 @default.
• W2601242481 creator A5034704814 @default.
• W2601242481 creator A5034884991 @default.
• W2601242481 creator A5043091366 @default.
• W2601242481 creator A5045441776 @default.
• W2601242481 creator A5051613962 @default.
• W2601242481 creator A5061348179 @default.
• W2601242481 creator A5066796042 @default.
• W2601242481 creator A5067038598 @default.
• W2601242481 creator A5069877747 @default.
• W2601242481 creator A5074731037 @default.
• W2601242481 creator A5078038970 @default.
• W2601242481 creator A5079480540 @default.
• W2601242481 creator A5082449165 @default.
• W2601242481 date "2017-02-01" @default.
• W2601242481 modified "2023-10-17" @default.
• W2601242481 title "Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: Update from CheckMate 142." @default.
• W2601242481 doi "https://doi.org/10.1200/jco.2017.35.4_suppl.519" @default.
• W2601242481 hasPublicationYear "2017" @default.
• W2601242481 type Work @default.
• W2601242481 sameAs 2601242481 @default.
• W2601242481 citedByCount "44" @default.
• W2601242481 countsByYear W26012424812017 @default.
• W2601242481 countsByYear W26012424812018 @default.
• W2601242481 countsByYear W26012424812019 @default.
• W2601242481 countsByYear W26012424812020 @default.
• W2601242481 countsByYear W26012424812021 @default.
• W2601242481 countsByYear W26012424812022 @default.
• W2601242481 crossrefType "journal-article" @default.
• W2601242481 hasAuthorship W2601242481A5003827387 @default.
• W2601242481 hasAuthorship W2601242481A5006249276 @default.
• W2601242481 hasAuthorship W2601242481A5009193095 @default.
• W2601242481 hasAuthorship W2601242481A5022734154 @default.
• W2601242481 hasAuthorship W2601242481A5025097010 @default.
• W2601242481 hasAuthorship W2601242481A5030715123 @default.
• W2601242481 hasAuthorship W2601242481A5034704814 @default.
• W2601242481 hasAuthorship W2601242481A5034884991 @default.
• W2601242481 hasAuthorship W2601242481A5043091366 @default.
• W2601242481 hasAuthorship W2601242481A5045441776 @default.
• W2601242481 hasAuthorship W2601242481A5051613962 @default.
• W2601242481 hasAuthorship W2601242481A5061348179 @default.
• W2601242481 hasAuthorship W2601242481A5066796042 @default.
• W2601242481 hasAuthorship W2601242481A5067038598 @default.
• W2601242481 hasAuthorship W2601242481A5069877747 @default.
• W2601242481 hasAuthorship W2601242481A5074731037 @default.
• W2601242481 hasAuthorship W2601242481A5078038970 @default.
• W2601242481 hasAuthorship W2601242481A5079480540 @default.
• W2601242481 hasAuthorship W2601242481A5082449165 @default.
• W2601242481 hasConcept C104317684 @default.
• W2601242481 hasConcept C121608353 @default.
• W2601242481 hasConcept C126322002 @default.
• W2601242481 hasConcept C143998085 @default.
• W2601242481 hasConcept C180754005 @default.
• W2601242481 hasConcept C185592680 @default.
• W2601242481 hasConcept C203092338 @default.
• W2601242481 hasConcept C2777701055 @default.
• W2601242481 hasConcept C2779767149 @default.
• W2601242481 hasConcept C2780030458 @default.
• W2601242481 hasConcept C2781187634 @default.
• W2601242481 hasConcept C526805850 @default.
• W2601242481 hasConcept C535046627 @default.
• W2601242481 hasConcept C55493867 @default.
• W2601242481 hasConcept C60748783 @default.
• W2601242481 hasConcept C61320498 @default.
• W2601242481 hasConcept C71924100 @default.
• W2601242481 hasConceptScore W2601242481C104317684 @default.
• W2601242481 hasConceptScore W2601242481C121608353 @default.
• W2601242481 hasConceptScore W2601242481C126322002 @default.
• W2601242481 hasConceptScore W2601242481C143998085 @default.
• W2601242481 hasConceptScore W2601242481C180754005 @default.
• W2601242481 hasConceptScore W2601242481C185592680 @default.
• W2601242481 hasConceptScore W2601242481C203092338 @default.
• W2601242481 hasConceptScore W2601242481C2777701055 @default.
• W2601242481 hasConceptScore W2601242481C2779767149 @default.
• W2601242481 hasConceptScore W2601242481C2780030458 @default.
• W2601242481 hasConceptScore W2601242481C2781187634 @default.
• W2601242481 hasConceptScore W2601242481C526805850 @default.
• W2601242481 hasConceptScore W2601242481C535046627 @default.
• W2601242481 hasConceptScore W2601242481C55493867 @default.
• W2601242481 hasConceptScore W2601242481C60748783 @default.
• W2601242481 hasConceptScore W2601242481C61320498 @default.
• W2601242481 hasConceptScore W2601242481C71924100 @default.
• W2601242481 hasIssue "4_suppl" @default.
• W2601242481 hasLocation W26012424811 @default.
• W2601242481 hasOpenAccess W2601242481 @default.
• W2601242481 hasPrimaryLocation W26012424811 @default.
• W2601242481 hasRelatedWork W1899127110 @default.
• W2601242481 hasRelatedWork W2005115324 @default.
• W2601242481 hasRelatedWork W2077201156 @default.
• W2601242481 hasRelatedWork W2122868421 @default.
• W2601242481 hasRelatedWork W2175776677 @default.

• next